A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

PHASE1TerminatedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions
Squamous-Cell Non-Small-Cell Lung Cancer
Interventions
DRUG

Bemarituzumab

Intravenous (IV) infusion

DRUG

Docetaxel

IV infusion

DRUG

Pembrolizumab

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Nab-paclitaxel

IV infusion

Trial Locations (39)

1200

Cliniques Universitaires Saint Luc, Brussels

2650

Universitair Ziekenhuis Antwerpen, Edegem

3500

Jessa Ziekenhuis - Campus Virga Jesse, Hasselt

9000

Universitair Ziekenhuis Gent, Ghent

10461

Montefiore Einstein Center for Cancer Care, The Bronx

11217

Taipei Veterans General Hospital, Taipei

13620

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do

15006

Complexo Hospitalario Universitario A Coruña Hospital Teresa Herrera, A Coruña

15211

University of Pittsburgh, Cancer Institute, Pittsburgh

28034

Hospital Universitario Ramon y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

29011

Hospital Regional Universitario de Malaga, Málaga

33076

Institut Bergonie, Bordeaux

33305

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan District

35033

Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou, Rennes

41013

Hospital Universitario Virgen del Rocio, Seville

69677

CHU de Lyon - Hopital Louis Pradel, Bron

70403

National Cheng Kung University Hospital, Tainan City

75020

Hôpital Tenon, Paris

86021

Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie, Poitiers

92868

University of California Irvine, Orange

94805

Institut Gustave Roussy, Villejuif

07960

Morristown Medical Center, Morristown

277-8577

National Cancer Center Hospital East, Kashiwa-shi

411-8777

Shizuoka Cancer Center, Sunto-gun

641-8510

Wakayama Medical University Hospital, Wakayama

62-500

Przychodnia Lekarska Komed Roman Karaszewski, Konin

30-727

Pratia Mcm Krakow, Krakow

31-501

Krakowskie Centrum Medyczne Sp zoo, Krakow

93-338

Instytut Centrum Zdrowia Matki Polki, Lodz

20-609

Instytut Genetyki i Immunologii GENIM Spzoo, Lublin

20-701

Centrum Medyczne Hope Clinic Sebastian Szklener, Lublin

05-400

Mazowieckie centrum leczenia, Otwock

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

08035

Hospital Universitari Vall d Hebron, Barcelona

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

08908

Institut Catala d Oncologia Hospitalet. Hospital Duran i Reynals, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05267470 - A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) | Biotech Hunter | Biotech Hunter